Disease · MONDO_0018935

hairy cell leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hairy cell leukemia. Diseases, record MONDO_0018935. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018935

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hairy cell leukemia; Open Targets
Open Targets ID: MONDO_0018935; Open Targets
Other names: HCL, HCL-C, leukemic reticuloendotheliosis; Open Targets
Disease Ontology: DOID:285; Disease Ontology
MeSH: D007943; MeSH
NCI Thesaurus: C7402; NCI Thesaurus
Orphanet: ORPHA:58017; Orphanet
Highest stage of its drugs: Approval, for 4 of its 24 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLADRIBINE	CHEMBL1619	Small molecule	Approval	DailyMed and EMA Human Drugs	7	5	5	Drugs and targets
MOXETUMOMAB PASUDOTOX	CHEMBL1743043	Antibody drug conjugate	Approval	ClinicalTrials.gov and FDA	7	5	4	Drugs and targets
PENTOSTATIN	CHEMBL1580	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	DailyMed and FDA	3	0	0	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	8	8	8	Drugs and targets
VEMURAFENIB	CHEMBL1229517	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
BINIMETINIB	CHEMBL3187723	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BL22	CHEMBL2109352		Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BRAF	RAF serine/threonine protein kinase	5	RAF serine/threonine protein kinase inhibitor; Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Approval	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	3	Interferon alpha/beta receptor agonist	Approval	https://conductscience.org/library/genes/3455	Drugs and targets
CD22	B-cell receptor CD22	2	CD22 binding agent	Approval	https://conductscience.org/library/genes/933	Drugs and targets
EEF2	Elongation factor 2	2	Elongation factor 2 inhibitor	Approval	https://conductscience.org/library/genes/1938	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	2	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	2	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
ADA	Adenosine deaminase	1	Adenosine deaminase inhibitor	Approval	https://conductscience.org/library/genes/100	Drugs and targets
ARAF	RAF serine/threonine protein kinase	1	RAF serine/threonine protein kinase inhibitor	Phase 1/2	https://conductscience.org/library/genes/369	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials29

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Phase 2	206	2023-08-21	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00923013	Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia	Phase 2	175	2025-08-08	Hairy Cell Leukemia	CLADRIBINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01829711	Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia	Phase 3	80	2018-08-27	Leukemia, Hairy Cell	MOXETUMOMAB PASUDOTOX	Its record names the disease	ClinicalTrials.gov
NCT01059786	Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia	Phase 2	69	2024-05-01	Hairy Cell Leukemia	BENDAMUSTINE, PENTOSTATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00586924	A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia	Phase 1	49	2019-04-02	Hairy Cell Leukemia	MOXETUMOMAB PASUDOTOX	Its record names the disease	ClinicalTrials.gov
NCT00496340	Phase II Trial of Pentostatin and Targeted Busulfan	Phase 2	42	2014-06-05	Hematologic Malignancies	BUSULFAN, PENTOSTATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01711632	BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Phase 2	36	2025-10-20	Hairy Cell Leukemia	VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT05537766	Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies	Phase 2	19	2026-03-10	Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia	BREXUCABTAGENE AUTOLEUCEL, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT03805932	Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia	Phase 1	18	2023-11-28	Hairy Cell Leukemia	MOXETUMOMAB PASUDOTOX, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00321555	LMB-2 to Treat Hairy Cell Leukemia	Phase 2	15	2019-04-05	Hairy Cell Leukemia	LMB-2	Its record names the disease	ClinicalTrials.gov

1 to 10 of 29

See all 29 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: Number of Participants Whose Cancer Shrinks or Disappears After Treatment	2 of 3	11 of 15	18	NCT03805932	Trial comparisons
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: Number of Participants With a Dose-limiting Toxicity (DLT)	0 of 3	0 of 15	18	NCT03805932	Trial comparisons
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	3 of 3	15 of 15	18	NCT03805932	Trial comparisons
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: deaths from any cause	1 of 3	0 of 15	18	NCT03805932	Trial comparisons
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: Number of Participants Who Are Minimal Residual Disease (MRD)-Free	2 of 3	11 of 15	18	NCT03805932	Trial comparisons
Moxetumomab - Dose Escalation 30 mcg/kg vs Moxetumomab - Dose Expansion 40 mcg/kg: serious adverse events	0 of 3	2 of 15	18	NCT03805932	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22355053	RESULT	1	PubMed
19672771	RESULT	1	PubMed
18603561	RESULT	1	PubMed
11474661	RESULT	1	PubMed
10764422	RESULT	1	PubMed
10552943	RESULT	1	PubMed
42308249	DERIVED	1	PubMed
41980020	DERIVED	2	PubMed
41060318	DERIVED	1	PubMed
38320179	DERIVED	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018935

GET https://conductscience.org/api/diseases/v1/MONDO_0018935/drugs?page=2

API reference For AI assistants